Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE)

Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.359
https://www.valueinhealthjournal.com/article/S1098-3015(13)02264-X/fulltext
Section Title : Disease-Specific Studies
Section Order : 344
First Page : A385
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02264-X&doi=10.1016/j.jval.2013.08.359
HEOR Topics :
Tags :
Regions :